Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

This was the stock's second consecutive day of gains.

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

which could take on rival Merck & Co's best-selling drug Keytruda. The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Merck (MRK) has reportedly been in talks to acquire Swiss biotech company MoonLake Immunotherapeutics (MLTX) for over $3 billion, according to the Financial Times. Snowflake (SNOW) will buy ...